Prediction of hearing loss due to cisplatin chemoradiotherapy

JAMA Otolaryngology - Head and Neck Surgery

Volumn 141, Issue 9, 2015, Pages 810-815

  Theunissen, Eleonoor A R ^a,b   Zuur, Charlotte L ^a,b   Joźiak, Katarzyna ^a   Lopez Yurda, Marta ^a   Hauptmann, Michael ^a   Rasch, Coen R N ^b   Van Der Baan, Sieberen ^b   De Boer, Jan Paul ^a   Dreschler, Wouter A ^c   Balm, Alfons J M ^a,b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

ARTICLE; AUDITORY THRESHOLD; BONE CONDUCTION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; COCHLEA; COHORT ANALYSIS; DRUG INDUCED DISEASE; DRUG MEGADOSE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FOLLOW UP; HEAD AND NECK CANCER; HEARING IMPAIRMENT; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PREDICTIVE VALUE; PURE TONE AUDIOMETRY; RADIATION DOSE; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SPEECH PERCEPTION; ADVERSE EFFECTS; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; INTENSITY MODULATED RADIATION THERAPY; INTRAVENOUS DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; OTORHINOLARYNGOLOGIC NEOPLASMS; PATHOLOGY; PATIENT EDUCATION; RADIATION RESPONSE; RISK FACTOR;

AUDIOMETRY, PURE-TONE; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; COCHLEA; COHORT STUDIES; COMBINED MODALITY THERAPY; DEAFNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFUSIONS, INTRAVENOUS; NEOPLASM STAGING; OTORHINOLARYNGOLOGIC NEOPLASMS; PATIENT EDUCATION AS TOPIC; RADIATION DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84942048659     PISSN: 21686181     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaoto.2015.1515     Document Type: Article

References (23)

1. Pignon JP, le Mare A, Maillard E, Bourhis J; MACH-NC Collaborative Group.Meta-Analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17, 346 patients. Radiother Oncol. 2009;92(1):4-14.
2. Pignon JP, Bourhis J, Domenge C, Design L; MACH-NC Collaborative Group, Meta-Analysis of Chemotherapy on Head and Neck Cancer. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-Analyses of updated individual data. Lancet. 2000;355(9208):949-955.
3. Hu R. The stigma attached to hearing impairment. Scand Audiol Suppl. 1996;43:12-24.
4. Prestes R, Daniela G. Impact of tinnitus on quality of life, loudness and pitch match, and high-frequency audiometry. Int Tinnitus J. 2009;15 (2):134-138.
5. Mujica-Mota M, Waissbluth S, Daniel SJ. Characteristics of radiation-induced sensorineural hearing loss in head and neck cancer: a systematic review. Head Neck. 2013;35(11):1662-1668.
6. Zuur CL, Simis YJ, Lamers EA, et al. Risk factors for hearing loss in patients treated with intensity-modulated radiotherapy for head-And-neck tumors. Int J Radiat Oncol Biol Phys. 2009;74(2):490-496.
7. Skinner R, Pearson AD, Amineddine HA, Mathias DB, Craft AW. Ototoxicity of cisplatinum in children and adolescents. Br J Cancer. 1990;61(6):927-931.
8. Zuur CL, Simis YJ, Lansdaal PE, et al. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-And-neck cancer: a multivariate analysis. Int J Radiat Oncol Biol Phys. 2007;68(5):1320-1325.
9. Honor HB, Bentzen SM, Mler K, Grau C. Sensori-neural hearing loss after radiotherapy for nasopharyngeal carcinoma: individualized risk estimation. Radiother Oncol. 2002;65(1):9-16.
10. Zuur CL, Simis YJ, Lansdaal PE, et al. Ototoxicity in a randomized phase III trial of intra-Arterial compared with intravenous cisplatin chemoradiation in patientswith locally advanced head and neck cancer. J Clin Oncol. 2007;25(24):3759-3765.
11. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation ofmissing blood pressure covariates in survival analysis. Stat Med. 1999;18(6): 681-694.
12. Raghunathan TE, Lepkowski JM, Hoenwijk V. A multivariate technique for multiply imputing missing values using a sequence of regression models. SurvMethodol. 2001;27(1):85-95.
13. Barnard J, Rubin DB. Small-sample degrees of freedom with multiple imputations. Biometrika. 1999;86:948-955.
14. Rubin DB. Multiple Imputation for Nonresponse in Survey. New York, NY: Wiley; 1987:75-79.
15. Dutch Health Insurance; article 2.10.a: Hulpmiddelen ter compensatie van beperkingen in het luisteren of bedienen van communicatieappartuur. http://www.handy-wijzer.nl/viewtext.asp ?OID=60443. Accessed July 15, 2015.
16. Johnson A, Tarima S, Wong S, Friedland DR, Runge CL. Statistical model for prediction of hearing loss in patients receiving cisplatin chemotherapy. JAMA Otolaryngol Head Neck Surg. 2013;139(3):256-264.
17. Dille MF, Wilmington D, McMillan GP, Helt W, Fausti SA, Konrad-Martin D. Development and validation of a cisplatin dose-ototoxicity model. J AmAcad Audiol. 2012;23(7):510-521.
18. American Speech-Language-Hearing Association. Audiologic management of individuals receiving cochleotoxic drug therapy. ASHA. 1994;36:11-19.
19. Low WK, Kong SW, Tan MG. Ototoxicity from combined cisplatin and radiation treatment: an in vitro study. Int J Otolaryngol. 2010;2010:523976. doi:10.1155/2010/523976.
20. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21(1):92-98.
21. Waissbluth S, Daniel SJ. Cisplatin-induced ototoxicity: transporters playing a role in cisplatin toxicity. Hear Res. 2013;299:37-45.
22. Pussegoda K, Ross CJ, Visscher H, et al; CPNDS Consortium. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther. 2013;94(2):243-251.
23. Steyerberg EW. Clinical Prediction Models. New York, NY: Springer; 2009:135.